These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Blum Murphy M; Amaya-Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J Cancer Med; 2024 May; 13(9):e7235. PubMed ID: 38716626 [TBL] [Abstract][Full Text] [Related]
3. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y; N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470 [TBL] [Abstract][Full Text] [Related]
4. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133 [TBL] [Abstract][Full Text] [Related]
5. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy. Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396 [TBL] [Abstract][Full Text] [Related]
6. Emerging data on nivolumab for esophageal squamous cell carcinoma. Hirose T; Yamamoto S; Kato K Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958 [TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience. Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma. Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102 [TBL] [Abstract][Full Text] [Related]
9. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). Meindl-Beinker NM; Betge J; Gutting T; Burgermeister E; Belle S; Zhan T; Schulte N; Maenz M; Ebert MP; Haertel N BMC Cancer; 2019 Mar; 19(1):231. PubMed ID: 30871493 [TBL] [Abstract][Full Text] [Related]
10. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Kadono T; Yamamoto S; Kato K Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845 [TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab for the treatment of advanced esophageal cancer. Harada K; Yamamoto S; Kato K Future Oncol; 2022 Jun; 18(18):2311-2319. PubMed ID: 35418242 [TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Shitara K; Ajani JA; Moehler M; Garrido M; Gallardo C; Shen L; Yamaguchi K; Wyrwicz L; Skoczylas T; Bragagnoli AC; Liu T; Tehfe M; Elimova E; Bruges R; Zander T; de Azevedo S; Kowalyszyn R; Pazo-Cid R; Schenker M; Cleary JM; Yanez P; Feeney K; Karamouzis MV; Poulart V; Lei M; Xiao H; Kondo K; Li M; Janjigian YY Nature; 2022 Mar; 603(7903):942-948. PubMed ID: 35322232 [TBL] [Abstract][Full Text] [Related]
14. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355 [TBL] [Abstract][Full Text] [Related]
15. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853 [TBL] [Abstract][Full Text] [Related]
16. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. Brahmer JR; Lee JS; Ciuleanu TE; Bernabe Caro R; Nishio M; Urban L; Audigier-Valette C; Lupinacci L; Sangha R; Pluzanski A; Burgers J; Mahave M; Ahmed S; Schoenfeld AJ; Paz-Ares LG; Reck M; Borghaei H; O'Byrne KJ; Gupta RG; Bushong J; Li L; Blum SI; Eccles LJ; Ramalingam SS J Clin Oncol; 2023 Feb; 41(6):1200-1212. PubMed ID: 36223558 [TBL] [Abstract][Full Text] [Related]
17. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect. Lee J; Kim B; Jung HA; La Choi Y; Sun JM Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan. Harada K; Yamamoto S; Kato K Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954 [TBL] [Abstract][Full Text] [Related]
19. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657 [TBL] [Abstract][Full Text] [Related]
20. The next generation of immunotherapy: keeping lung cancer in check. Somasundaram A; Burns TF J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]